In plain terms — Daxor Corp
No daily net asset value is published for this fund on our feed, so we cannot say whether it trades above or below its assets.
Guided view hides the statistical panels. Switch to Expert view in the grey bar to see them. Nothing here is advice.
Price and NAV, past year
Snapshot
Valuation vs. history
| Window | Average prem/disc | Std. dev. | Z-score | Observations |
|---|---|---|---|---|
| 3 months | — | — | — | 0 |
| 6 months | — | — | — | 0 |
| 1 year | — | — | — | 0 |
| 3 years | — | — | — | — |
| 5 years | — | — | — | — |
Current contemporaneous premium/discount — (close Oct 19, 2026 vs NAV —). 1-year range — to —. A negative Z-score means a wider discount than the window average — not that the fund is undervalued.
Performance
| Series | 1M | 3M | YTD | 1Y | 3Y (ann.) | 5Y (ann.) |
|---|---|---|---|---|---|---|
| Market price return | -14.06% | -9.72% | -33.29% | -24.02% | +3.18% | -2.28% |
| Market price total return | -14.06% | -9.72% | -33.29% | -24.02% | +3.18% | -2.28% |
| NAV return | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Through Oct 19, 2026. Total return reinvests distributions at the series value on the ex-date. Cumulative ≤ 1 year, annualised beyond.
About the fund
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
CEF Explorer research page for Daxor Corp. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.